Pharma Focus Asia

Tonix Pharmaceuticals Plans New Clinical Scale Manufacturing Facility in US

Introduction:

Tonix Pharmaceuticals Holding Corp, plans to open new manufacturing facility. The new R&D facility will address Advanced Development Center (ADC) for vaccine programs.

Features:

The new Advanced Development Center (ADC) will support research, development and analytical capabilities which also includes the production of quality trial vaccines for infectious diseases such as COVID-19.

The Advanced Development Center (ADC),comprises of single-use bioreactors and purification suites. Moreover when the facility becomes fully operational, Good Manufacturing Practice (GMP) production of vaccines for clinical trialswill have the capacity to produce sterile vaccines in glass bottles.

The facility is expected to hire 70 employees including scientists, researchers, manufacturing and technical support staff.

The construction of the site has begun and expected to be fully operational in first half of 2022.

Specifications:

NameTonix Pharmaceuticals
TypeNew Construction
Year2022
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024